Product information and disease descriptionPlace of product in therapyApproaches to treatment
Care management intervention strategies
12 evidence topics · 8 sources
Delphi consensus: counseling before and after APOL1 testing
“Patients should have a clear understanding of the purpose of the APOL1 test and the potential implications of the result before the test is taken” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When health care professionals discuss APOL1 testing with their patients, they should be honest and transparent about the current understanding of APOL1, take time to discuss APOL1 with patients, listen to their concerns, answer questions, and provide information sources that are balanced, easy to use and understand, and reliable” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a patient with CKD is confirmed to have a high-risk APOL1 genotype, the clinician should:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Encourage the patient to participate in clinical trials for which they are eligible” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inform the patient about other modifiable risk factors and renoprotective measures (lifestyle changes, BP control)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is no established best practice for counseling patients about APOL1 testing; further research is required to define best practice” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nephrology trainees need to be educated to be able to confidently deliver effective counseling to patients about APOL1 testing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delphi consensus: barriers to testing
“Clinicians’ lack of confidence in communicating the findings from APOL1 testing to patients in a clear and effective way that minimizes patient confusion and misunderstanding is a major barrier to APOL1 testing in patients with nephropathy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Low levels of trust in the medical establishment could be a barrier to APOL1 testing in the Black community” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lack of specific treatment and concerns regarding insurance reimbursement for genetic testing and potential discrimination on the basis of APOL1 genotype (e.g., life insurance, health insurance, job security) may be barriers to physicians educating patients about APOL1-associated nephropathy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delphi consensus: disease awareness and community education
“There are low levels of awareness of APOL1-associated nephropathy in the Black community” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nephrologists, primary care providers, nurses, community leaders, and patient networks all have an important role to play in educating Black patients with nephropathy about the APOL1 gene” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To improve awareness of APOL1 among the patient community, health care professionals should work with community leaders and community groups and should provide education in a setting that is familiar and comfortable for patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KDIGO Controversies Conference: requirements for operating APOL1 testing and community engagement
“For operationalizing genetic testing, the following are necessary: a validated test in a registered laboratory with appropriately trained staff; pre- and post-testing counseling; availability of co-designed educational material tailored to levels of health literacy; and a process for early surveillance and intervention, including in children. In high prevalence populations, community leaders, content experts, and faith leaders should be engaged to facilitate community education initiatives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Authentic community engagement is critical in designing and implementing APOL1 prevalence and research studies, testing in clinical care, as well as communicating how findings inform recommendations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Established guidance on disclosure of genetic test results to family members (cascade testing) should be followed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KDIGO Controversies Conference: principles for deciding on APOL1 testing
“Appropriately qualified counseling is available to support voluntary and informed decision-making about testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CKD care and screening are available AND APOL1 test results could change management (e.g., an effective treatment for APOL1 is available OR results could lead to increased surveillance for CKD OR results would inform risk/benefit evaluation in decision-making about living kidney donation).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KDIGO Controversies Conference: community outreach for clinical trial participation
“To raise awareness about CKD and APOL1 kidney disease as well as encourage participation in clinical trials, community outreach is required to develop, strengthen, and sustain relationships with trusted community leaders and partners.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As the understanding of and treatments for APOL1 kidney disease are further developed, engagement and education of communities and health care professionals, including those in primary care, will be key in improving patient health in all regions affected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic counseling and surveillance after a high-risk result
“All individuals should receive genetic counseling before and after APOL1 genetic testing and be advised about potential for increased cost of health insurance that may be associated with detection of a high-risk APOL1 genotype. When individuals are noted to have a high-risk genotype, physicians may consider more frequent screening for reduced GFR and proteinuria to identify AMKD at an early stage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KDIGO 2024 CKD guideline: genetic testing and counseling
Manufacturer-sponsored no-cost APOL1 testing program
Returning APOL1 results to patients with hypertension: randomized trial
“This pragmatic randomized clinical trial randomly assigned 2050 adults of African ancestry with hypertension and without existing chronic kidney disease in 2 US health care systems from November 1, 2014, through November 28, 2016; the final date of follow-up was January 16, 2018.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 3 months, the mean (SD) change in systolic blood pressure was significantly greater in patients with high-risk APOL1 genotypes vs those with low-risk APOL1 genotypes (6 [18] vs 3 [18] mm Hg; P = .004) and controls (6 [18] vs 3 [19] mm Hg; P = .01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer disease awareness campaign
Transplant center APOL1 testing policies: Delphi panel
“Key elements of consensus include the following: ask potential donors about African ancestry rather than race; make testing decisions only after discussion with donors; encourage disclosure of test results to blood relatives and organ recipients but do not require it; use test results to inform decision making, but never for unilateral decisions by transplant programs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote